Department of Radiotherapy and Radiation Oncology, Medical Faculty Carl Gustav Carus, Technical University of Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
Strahlenther Onkol. 2013 Jul;189(7):529-34. doi: 10.1007/s00066-013-0361-y. Epub 2013 May 25.
The present retrospective study was initiated to characterize the effect of oncological treatments in children and adolescents on bone and soft tissues, and to assess their dependence on radiation dose and age at exposure.
The study included 146 patients treated between 1970 and 1997. All patients received external beam radiotherapy to the trunk or extremities, but no cranial irradiation. Median age at treatment was 8.8 years. Patients were screened at 18 years (median time interval since treatment 9.2 years, range 0.9-17.7 years) for pathological changes in the skeletal system and soft tissues (scoliosis, kyphosis, bony hypoplasia, soft tissue defects, asymmetries), which were classified as minor/moderate (grade 1) or substantial (grade 2).
Pathological findings were recorded in 75/146 patients (51 %). These were scored as minor in 44 (59 %) and substantial in 31 patients (41 %). Most pathological changes occurred in children treated under the age of 6 years. At 6 years and older, only doses > 35 Gy caused an effect, and no substantial changes were seen for treatment ages exceeding 12 years. Significant effects of radiation dose and age at exposure were observed for kyphoscoliosis (with vertebral body dose gradients < 35 Gy), hypoplasia and soft tissue defects and asymmetrical growth.
Tolerance doses of 20 Gy need to be respected for growing bone, particularly in children treated under the age of 6 years. The late treatment sequelae analysed in the present study are largely avoided with the use of current therapeutic protocols. However, the systematic evaluation, documentation and continuous analysis of adverse events in paediatric oncology remains essential, as does the evaluation of novel radio(chemo)therapeutic approaches.
本回顾性研究旨在描述儿童和青少年接受肿瘤治疗对骨骼和软组织的影响,并评估其对辐射剂量和暴露年龄的依赖性。
本研究纳入了 1970 年至 1997 年间接受治疗的 146 名患者。所有患者均接受了躯干或四肢的外照射放疗,但未进行颅脑照射。中位治疗年龄为 8.8 岁。患者在治疗后 18 岁时(自治疗开始的中位时间间隔为 9.2 年,范围为 0.9-17.7 年)进行骨骼系统和软组织(脊柱侧凸、后凸、骨发育不全、软组织缺损、不对称)的病理变化筛查,这些变化分为轻微/中度(1 级)或显著(2 级)。
146 名患者中有 75 名(51%)出现了病理发现。其中 44 名(59%)为轻微,31 名(41%)为显著。大多数病理变化发生在 6 岁以下的儿童中。6 岁及以上患者仅在剂量>35Gy 时会产生影响,且在 12 岁以上的治疗年龄时不会出现显著变化。辐射剂量和暴露年龄对脊柱侧后凸、发育不全和软组织缺损以及不对称生长均有显著影响。
对于生长中的骨骼,特别是 6 岁以下儿童,需要遵守 20Gy 的耐受剂量。本研究分析的迟发性治疗后遗症在很大程度上可以避免当前治疗方案的应用。然而,对儿科肿瘤学中不良事件的系统评估、记录和持续分析以及新型放化疗方法的评估仍然至关重要。